1 Min Read
Nov 20 (Reuters) - Novartis AG
* Novartis drug Tasigna (nilotinib) secures eu approval for first and second-line treatment of ph+ cml-cp in children Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.